June 2015

Contents

Editorial

• May/June 2015: Volume 16 Number 5/6

In memory

• Remembering Professor Martin Fisher

Treatment alerts

• Early START results recommend ART for all study participants: starting HIV meds when the CD4 count is above 500 reduces AIDS-related events

Conference reports

• 21st Annual BHIVA Conference, 21-24 April 2015, Brighton

• BHIVA pregnancy audit 2013 to 2014

• Transmitted drug resistance in HIV positive pregnant women

• Primary HIV infection and early use of ART

• Rectal STIs and viral load in HIV positive men on and off ART

• Impact of age and HIV on use of non-HIV meds: early results on health care use in the POPPY study

• Other short reports from BHIVA:

• 2015 Conference on Retroviruses and Opportunistic Infections (CROI), 23-26 February 2015, Seattle

• Elvitegravir in children and adolescents

• PK of ARVs in pregnancy: rilpivirine, etravirine and raltegravir

• HIV and cardiovascular disease

• 5th International Workshop on HIV & Women
, 21-22 February 2015, Seattle, Washington

• Pharmacokinetics in pregnancy: darunavir/r and etravirine

• Low prolactin and high 20alpha-HSD might contribute to ART-associated progesterone deficits in pregnancy

• Pregnancy rates among women using ART and hormonal contraceptives in Kenya

• Adolescents at increased risk of vertical transmission and poor pregnancy outcome in South Africa

• Gender difference in virological response to ART

Antiretrovirals

• Generic dolutegravir submitted to FDA for tentative approval

• EMA approves coformulated atazanavir/cobicistat

• Dual F/TAF formulation under evaluation by EMA

Treatment access

• Lopinavir/ritonavir pellets tentatively approved by the FDA

• Sofosbuvir access: new patent challenges to sofosbuvir

Guidelines

• US guidelines shift to integrase-based combinations for first-line treatment (2015): Atripla relegated due to side effects

• EACS guidelines (2015): translations in 11 languages now available online

• Recommendations for management of bone health in people living with HIV

TB coinfection

• New clinical trial for extensively drug resistant TB (XDR-TB)

• MSF report and call to action: Promising new TB drugs are not reaching patients

HIV prevention and transmission

• Methmephangee – ChemSex vs recreational drug use: a proposed definition for health workers

Basic science and immunology

• Timing of very early ART to limit early HIV-related mucosal dysfunction

• Broad CD8 T cell responses are required to overcome dominance of CTL escape in the latent HIV reservoir

• Broadly neutralising antibody suppresses HIV in clinical trial

Other news

• WHO statement for public disclosure of clinical trial results

PDFs

• May/June 2015: Volume 16 Number 5/6